Zentalis Pharmaceuticals (ZNTL) Operating Expenses (2019 - 2026)

Zentalis Pharmaceuticals' Operating Expenses history runs 8 years deep, the most recent figure standing at $37.9 million for Q1 2026.

• In Q1 2026, Operating Expenses fell 17.03% year-over-year to $37.9 million; the TTM figure through Mar 2026 stood at $145.0 million (down 39.29% YoY), while the FY2025 annual figure was $152.8 million, down 40.91% from the prior year.
• Operating Expenses for Q1 2026 stood at $37.9 million, up from $37.4 million in the prior quarter.
• The five-year high for Operating Expenses was $103.9 million in Q2 2023, with the low at $33.7 million in Q3 2025.
• The 5-year median for Operating Expenses is $57.9 million (2022), against an average of $57.4 million.
• The sharpest annual moves came in 2023 and 2025: Operating Expenses soared 63.75% in 2023, then tumbled 51.26% in 2025.
• Zentalis Pharmaceuticals' Operating Expenses stood at $51.8 million in 2022, then soared by 31.24% to $67.9 million in 2023, then climbed by 12.94% to $76.7 million in 2024, then sank by 51.26% to $37.4 million in 2025, then grew by 1.24% to $37.9 million in 2026.
• Business Quant data shows ZNTL's Operating Expenses at $37.9 million in Q1 2026, $37.4 million in Q4 2025, and $33.7 million in Q3 2025.